These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 2196621

  • 1. Naltrexone in autistic children: a double-blind and placebo-controlled study.
    Campbell M, Anderson LT, Small AM, Locascio JJ, Lynch NS, Choroco MC.
    Psychopharmacol Bull; 1990; 26(1):130-5. PubMed ID: 2196621
    [Abstract] [Full Text] [Related]

  • 2. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.
    Kolmen BK, Feldman HM, Handen BL, Janosky JE.
    J Am Acad Child Adolesc Psychiatry; 1995 Feb; 34(2):223-31. PubMed ID: 7896655
    [Abstract] [Full Text] [Related]

  • 3. Naltrexone in autistic children: behavioral symptoms and attentional learning.
    Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M.
    J Am Acad Child Adolesc Psychiatry; 1993 Nov; 32(6):1283-91. PubMed ID: 8282676
    [Abstract] [Full Text] [Related]

  • 4. Naltrexone in young autistic children: replication study and learning measures.
    Kolmen BK, Feldman HM, Handen BL, Janosky JE.
    J Am Acad Child Adolesc Psychiatry; 1997 Nov; 36(11):1570-8. PubMed ID: 9394942
    [Abstract] [Full Text] [Related]

  • 5. Naltrexone plasma levels, clinical response and effect on weight in autistic children.
    Gonzalez NM, Campbell M, Small AM, Shay J, Bluhm LD, Adams PB, Foltz RL.
    Psychopharmacol Bull; 1994 Nov; 30(2):203-8. PubMed ID: 7831456
    [Abstract] [Full Text] [Related]

  • 6. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.
    Willemsen-Swinkels SH, Buitelaar JK, van Engeland H.
    Biol Psychiatry; 1996 Jun 15; 39(12):1023-31. PubMed ID: 8780837
    [Abstract] [Full Text] [Related]

  • 7. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
    Akhondzadeh S, Erfani S, Mohammadi MR, Tehrani-Doost M, Amini H, Gudarzi SS, Yasamy MT.
    J Clin Pharm Ther; 2004 Apr 15; 29(2):145-50. PubMed ID: 15068403
    [Abstract] [Full Text] [Related]

  • 8. [Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].
    Leboyer M, Bouvard MP, Launay JM, Recasens C, Plumet MH, Waller-Perotte D, Tabuteau F, Bondoux D, Dugas M.
    Encephale; 1993 Apr 15; 19(2):95-102. PubMed ID: 8275903
    [Abstract] [Full Text] [Related]

  • 9. Naltrexone and communication skills in young children with autism.
    Feldman HM, Kolmen BK, Gonzaga AM.
    J Am Acad Child Adolesc Psychiatry; 1999 May 15; 38(5):587-93. PubMed ID: 10230191
    [Abstract] [Full Text] [Related]

  • 10. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F.
    Pediatrics; 2004 Nov 15; 114(5):e634-41. PubMed ID: 15492353
    [Abstract] [Full Text] [Related]

  • 11. Clinical effects of naltrexone on autistic behavior.
    Zingarelli G, Ellman G, Hom A, Wymore M, Heidorn S, Chicz-DeMet A.
    Am J Ment Retard; 1992 Jul 15; 97(1):57-63. PubMed ID: 1497864
    [Abstract] [Full Text] [Related]

  • 12. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study.
    Cueva JE, Overall JE, Small AM, Armenteros JL, Perry R, Campbell M.
    J Am Acad Child Adolesc Psychiatry; 1996 Apr 15; 35(4):480-90. PubMed ID: 8919710
    [Abstract] [Full Text] [Related]

  • 13. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.
    Grant JE, Kim SW, Odlaug BL.
    Biol Psychiatry; 2009 Apr 01; 65(7):600-6. PubMed ID: 19217077
    [Abstract] [Full Text] [Related]

  • 14. Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children.
    Ernst M, Devi L, Silva RR, Gonzalez NM, Small AM, Malone RP, Campbell M.
    Psychopharmacol Bull; 1993 Apr 01; 29(2):221-7. PubMed ID: 8290669
    [Abstract] [Full Text] [Related]

  • 15. The effects of naltrexone in autistic children: report of two cases.
    Akkök F.
    Turk J Pediatr; 1995 Apr 01; 37(1):19-23. PubMed ID: 7732604
    [Abstract] [Full Text] [Related]

  • 16. Effects of acute administration of naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children.
    Herman BH, Hammock MK, Arthur-Smith A, Kuehl K, Appelgate K.
    Dev Pharmacol Ther; 1989 Apr 01; 12(3):118-27. PubMed ID: 2721334
    [Abstract] [Full Text] [Related]

  • 17. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.
    Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou E, Soorya L, Hollander E.
    Int Clin Psychopharmacol; 2006 Nov 01; 21(6):363-7. PubMed ID: 17012983
    [Abstract] [Full Text] [Related]

  • 18. Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder.
    Niederhofer H, Staffen W, Mair A.
    Hum Psychopharmacol; 2003 Jul 01; 18(5):389-93. PubMed ID: 12858327
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder.
    Elchaar GM, Maisch NM, Augusto LM, Wehring HJ.
    Ann Pharmacother; 2006 Jun 01; 40(6):1086-95. PubMed ID: 16735648
    [Abstract] [Full Text] [Related]

  • 20. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
    Baghdadli A, Gonnier V, Aussilloux C.
    Encephale; 2002 Jun 01; 28(3 Pt 1):248-54. PubMed ID: 12091786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.